In addition to its effects on B-cell functions, our human cell data suggest that BTK inhibition via fenebrutinib could act on microglia to attenuate pathogenic neuroinflammation associated with FcγR activation (Fig. 6) and may therefore help reduce progressive neurodegeneration that results from chronic CNS inflammation in MS. Here, FCGR2A is linked to myeloid sarcoma.